Sidley Austin represented OMERS Life Sciences in the transaction, while Latham & Watkins advised Verona Pharma and Sullivan & Cromwell represented Oaktree Capital Management, L.P. Verona...
You must be a Standard 1 Year member to access this content.
Sidley Austin represented BigHat Biosciences, Inc. in the transaction. BigHat Biosciences, Inc. (“BigHat”), announced a licensing collaboration with Synaffix B.V. (“Synaffix”), a Lonza company (SWX:LONN). BigHat’s...
You must be a Standard 1 Year member to access this content.
Sidley Austin is advising GlycoMimetics, Inc. on the transaction, and Gibson, Dunn & Crutcher is advising Crescent Biopharma, Inc. GlycoMimetics, Inc. (NASDAQ: GLYC) announced it has...
You must be a Standard 1 Year member to access this content.
Sidley Austin represented Ocuphire Pharma, Inc. in the transaction, and Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan represented Opus Genetics Inc. Wilson Sonsini Goodrich & Rosati...
You must be a Standard 1 Year member to access this content.
Sidley Austin advised Healthcare Royalty on the deal. HealthCare Royalty, a leading royalty acquisition company, announced its US$250 million non-dilutive note purchase agreement with OPKO Health,...
You must be a Standard 1 Year member to access this content.
Sidley Austin represented Biolojic Design, Ltd. in the deal. Biolojic Design, Ltd. (Biolojic), a biotechnology company, announced it has entered into a multi-target drug discovery collaboration...
You must be a Standard 1 Year member to access this content.
Sidley Austin represented Carlin Consumer Health in the transaction, and Jones Day represented American Pacific Group. Carlin Consumer Health (“Carlin”) announced its acquisition of PENETREX® (“Penetrex”)...
You must be a Standard 1 Year member to access this content.
Sidley Austin represented BigHat Biosciences in the transaction. BigHat Biosciences, a biotechnology company with an artificial intelligence/machine learning-guided antibody discovery and development platform, announced its collaboration...
You must be a Standard 1 Year member to access this content.
Sidley Austin represented Pyxis Oncology, Inc. on the deal. Pyxis Oncology, Inc. (Nasdaq: “PYXS”), a clinical stage company, announced that it agreed to sell 8,849,371 shares of...
You must be a Standard 1 Year member to access this content.
Sidley Austin represented Sagard Healthcare in the transaction, and Cooley represented MannKind Corporation. Sagard Healthcare (Sagard) announced it entered into a royalty purchase agreement, under which...
You must be a Standard 1 Year member to access this content.
Sidley Austin represented Praxis Precision Medicines, Inc. in the transaction, and Ropes & Gray advised Tenacia. Praxis Precision Medicines, Inc. (NASDAQ: PRAX) announced it has entered...
You must be a Standard 1 Year member to access this content.
Sidley Austin LLP represented Novo Nordisk Inc. in the matter. Novo Nordisk (NYSE: NVO) announced its collaboration with Evotec SE (NASDAQ: EVO) to launch LAB eN² (pronounced Lab...
You must be a Standard 1 Year member to access this content.
